10 The aim of the present study is
to compare between the effects of chlorpromazine (first generation) and olanzapine (second Protease Inhibitor Library generation) on body weight, waist circumferences, serum glucose concentration and lipid profile in schizophrenic patients. A total of 70 patients (age 25–53-years old) of both sexes participated in this study. They were divided in two groups of 35 patients each. The patients were randomly allocated to receive any of two different treatments. One group of patients (n = 35) received treatment with 5 mg daily oral olanzapine and the second group (n = 35) received 100 mg three times daily oral Chlorpromazine. Another 35 healthy individuals, involved in the study as a control group. The study was a randomized controlled comparative study performed over a period of one year
from June 2011 to July 2012. The patients were seen at Psychiatric Unit in IBN-SINA ubiquitin-Proteasome pathway Teaching Hospital in Mosul, Iraq. The study protocol was approved by the Ethics Committees of the College of pharmacy and Mosul Health Administration. Inclusion criteria were a diagnosis of schizophrenia made according to DSM-IV criteria of the American Psychiatric Association (APA). The diagnosis of all the patients was confirmed by consultant psychiatrists at Psychiatric Unit in IBN-SINA Teaching Hospital. The study included those patients who had not received antipsychotic treatment in the last 6 months (long washout period). The exclusion criteria in
this study were patients who had received prior antipsychotic medication in the last 6 months. Patients having any type of cardiovascular disorder, whether under treatment or not, and known patients of diabetes (even if Tryptophan synthase having fasting blood sugar controlled below 110 mg/dl by any diabetic medication) all were excluded from the study. Pregnant or lactating patients, patients having family history of diabetes and patients having chronic medical illness were also excluded. The patients’ baseline body weight, waist circumference, BMI, fasting blood sugar and lipid profile were assessed before the treatment was initiated, and after 3 months of the treatment. Total serum TG, HDL, TC and fasting blood glucose levels of the patients and controls were measured by using standard commercial kits. Serum LDL concentration was calculated by using Friedewald equation. Calculation of BMI was done for each patient and control by using Quetelet index (Body weight/Height2). Waist circumference in (cm) was determined with a standard tape measure, as the point midway between the costal margin and iliac crest in the mid-axillary’s line, with the subject standing and breathing normally. Statistical methods: Standard statistical methods were used to determine the mean and standard deviation (SD). Paired student t-test was used to compare patients and control characteristics and the results between before and after drug therapy. P-value of ≤0.